Rekombinanter VEGFR2 (Ramucirumab Biosimilar) Antikörper

Produktnummer ABIN7795122

Der Maus Monoklonal anti-VEGFR2 (Ramucirumab Biosimilar) Antikörper wird verwendet zum Nachweis von VEGFR2 (Ramucirumab Biosimilar) in Proben von Human. Er wurde validiert für FACS und in vivo.

Kurzübersicht für Rekombinanter VEGFR2 (Ramucirumab Biosimilar) Antikörper (ABIN7795122)

Target: VEGFR2 (Ramucirumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGFR2 (Ramucirumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-VEGFR2 (Ramucirumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody

Produktmerkmale: What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human VEGFR2

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu VEGFR2 (Ramucirumab Biosimilar)

Target: VEGFR2 (Ramucirumab Biosimilar)

Andere Bezeichnung: Ramucirumab Biosimilar

Substanzklasse: Biosimilar